Is dyslipidemia a risk factor for trastuzumab-induced cardiotoxicity in breast cancer patients? A systematic review and meta-analysis

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2023

Autores

Pinho, J (Autor) Outra; Carvalho, M (Autor) FMUP; Paiva, M (Autor) Outra; Teixeira Tavares, N (Autor) Outra; Cristina Costa Santos (Autor) FMUP; Sousa, C (Autor) FMUP

Revista

Título: Revista Portuguesa de Cardiologia

Vol. 42

Páginas: 961-984

ISSN: 0870-2551

Editora: Sociedade Portuguesa De Cardiologia

Indexação

ISI Web of Knowledge - 0 Citações

Outras Informações

ID Authenticus: P-00Z-R9C

DOI: 10.1016/j.repc.2022.10.016

Abstract (EN): Introduction: Breast cancer patients undergoing trastuzumab therapy have greater risk of cardiovascular disease. Risk factors for this effect have been proposed. However, the role of dyslipidemia is not completely understood. This systematic review aimed to explore the role of dyslipidemia in trastuzumab-induced cardiotoxicity. Methods: The investigators searched MEDLINE, Scopus, and Web of Science up to October 25, 2020. A random-effects model was used to determine pooled estimates of the results. The primary endpoint was trastuzumab-induced cardiotoxicity in patients with and without dyslipidemia. Results: A total of 39 studies were selected for inclusion in our systematic review assessing 21 079 patients. One study demonstrated a statistically significant association between dyslipidemia and cardiotoxicity (OR=2.28, 95% CI 1.22-4.26, p=0.01). In all other studies, no such association was observed. Twenty-one studies including 6135 patients were eligible for meta-analysis. In this meta-analysis of unadjusted data, dyslipidemia was significantly associated with cardiotoxicity (OR=1.25, 95% CI 1.01-1.53, p=0.04, I2=0%), however, a subgroup analysis of studies reporting adjusted measures did not demonstrate a significant association (OR=0.89, 95% CI 0.73-1.10, p=0.28, I2=0%).

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 24